TL;DR
- 1.Ta1 has 11,000+ human subjects across 30 controlled trials. More clinical data than almost any other peptide in the biohacking space.
- 2.In 2025: null result in sepsis (1,089 patients). Also in 2025: 44% infection reduction in pancreatitis. These results clarify what Ta1 actually is.
- 3.Ta1 is not an immune booster. It recalibrates overactivated, exhausted immune systems. That pattern appears in pancreatitis, long COVID, and ME/CFS.
- 4.Standard dose is 1.6 mg SC twice weekly for 26 weeks. Counterintuitively, peak hepatitis B response appears months after stopping. Most users quit too early.
- 5.Ta1 moved to FDA Category 1 in April 2026. A licensed physician can now prescribe it and a 503A compounding pharmacy can fill it. PCAC review is July 2026.
Thymosin Alpha-1 has been injected into more than 11,000 humans across 30 controlled trials. Then in January 2025, the largest trial yet showed it does nothing for sepsis. Most people stopped reading there. That is a mistake.
Human subjects enrolled in Thymosin Alpha-1 clinical trials since 1985, more than almost any other peptide discussed in the biohacking space.
The null sepsis result is the most useful thing researchers have learned about Ta1 in decades. It clarifies what this peptide is and is not. Ta1 is not an immune booster. It is an immune modulator, a peptide that recalibrates a specific kind of immune dysfunction. When that dysfunction is present, the data is striking. When it is not, Ta1 does nothing.
That distinction changes everything about who should take it and why.
Think of your immune system like a car engine. Some people have an engine that runs cold and sluggish -- easy to get sick, slow to recover. Others have an engine that runs hot and rough -- chronic inflammation, autoimmune flares, never quite settled. Thymosin Alpha-1 does not add fuel. It recalibrates the thermostat. It works on the second type of engine, not the first.
What Thymosin Alpha-1 Actually Does to Your Immune System
Ta1 is a 28-amino-acid peptide that your thymus gland naturally produces. Thymic output declines sharply after age 25, which is one reason immune resilience tends to fall with age. By your 50s, output is a fraction of what it was at 20.
The peptide binds to Toll-like receptors 2 and 9 on dendritic cells and T cells. That receptor activation shifts immune activity toward the Th1 arm, the side of the immune system responsible for fighting viruses and abnormal cells, and for resolving chronic infections.
The human trial results tell a clearer story than any mechanism summary.
In a 2021 study in Open Forum Infectious Diseases, researchers gave Ta1 to 15 COVID-19 patients and measured specific immune markers in their blood. A single course significantly reduced CD38 expression on CD8+ T cells (P=0.044), lowered intracellular IL-6 in those same cells (P=0.050), and produced a sharp reduction in HLA-DR activation (P=0.001). These are not theoretical effects. They are directly measurable changes in the cells driving the inflammatory damage seen in severe COVID-19.
"CD38 expression in CD8+ T cells correlated positively with blood IFNgamma mRNA levels (rho=0.589, P=.021) -- the first direct link between thymosin alpha-1, CD38, and interferon signaling in humans."
Open Forum Infectious Diseases, 2021
The CD38/IFNgamma axis is the same pathway implicated in long COVID immune exhaustion. That is not a coincidence.
Why the Biggest Sepsis Trial Found No Benefit, and What It Actually Means
The TESTS trial was the definitive test of Ta1 for sepsis. Published in the BMJ in January 2025, it enrolled 1,089 patients across multiple centers in China, randomized them to Ta1 or placebo, and measured 28-day mortality. The result: 23.4% mortality in the Ta1 arm versus 24.1% in placebo. Hazard ratio 0.99. P=0.93. Statistically, Ta1 and saline water performed identically.
This matters. Four decades of smaller, single-center trials had produced positive signals for sepsis. The TESTS investigators analyzed why earlier trials looked so promising. Their conclusion pointed squarely at single-center publication bias: the positive results were an artifact of study design, not biology.
Forty years of promising smaller trials were probably wrong. The well-designed Phase 3 trial revealed the truth. This is not unusual in medicine, but it is striking for a peptide with this much accumulated enthusiasm behind it.
Where Ta1 works
Immune exhaustion and chronic dysregulation. Sustained viral infections (hepatitis B, C). Post-acute infection sequelae. Severe acute pancreatitis. Long COVID and ME/CFS immune exhaustion. Contexts where the immune system is simultaneously overactivated and functionally depleted.
Where Ta1 does not work
Acute bacterial sepsis in unselected patients. General immune boosting in healthy adults. Any context where the immune system is functioning at baseline and simply needs to fight harder.
Ta1 is not anti-infective. It does not kill bacteria. It resets the immune regulatory layer, and that layer is only meaningfully dysregulated in specific conditions.
Severe Acute Pancreatitis: Where the Evidence Is Strongest Right Now
In the same year the TESTS sepsis trial failed, a separate meta-analysis in Frontiers in Immunology (2025) pooled five randomized controlled trials covering 706 patients with severe acute pancreatitis. This is a condition where the immune response to pancreatic damage becomes pathologically dysregulated -- exactly the pattern Ta1 addresses.
Reduction in serious extrapancreatic infections among severe acute pancreatitis patients receiving Thymosin Alpha-1, compared to standard care alone (Frontiers in Immunology, 2025, meta-analysis of 5 RCTs, 706 patients).
Ta1 raised CD4+ cell counts, improved the CD4+/CD8+ ratio, cut bloodstream infections by 40%, and reduced abdominal infections by 62%. APACHE II severity scores, a direct measure of how sick patients were, dropped significantly in the Ta1 group.
This is the clearest human evidence for Ta1 that currently exists. And it fits the modulator model perfectly. Pancreatitis patients have the exact kind of immune dysfunction Ta1 addresses. Sepsis patients, on average, do not.
The same peptide. The same dose. Opposite results in different immune contexts. That tells you almost everything.
The Long COVID Connection Most Articles Completely Miss
Long COVID affects an estimated 65 million people globally. About 51% of cases overlap with ME/CFS criteria. Both share a common immune signature: persistent T-cell hyperactivation alongside functional exhaustion. The immune system is stuck in a loop -- activated, inflamed, but unable to resolve.
That is the exact immune profile Ta1 modulates. A 2023 PMC study found that Ta1 treatment in post-acute SARS-CoV-2 patients measurably restored immune homeostasis, specifically reducing the CD38/IFNgamma activation pattern that correlates with fatigue severity and symptom burden in long COVID.
No large randomized trial for long COVID specifically exists yet. But the mechanistic fit is unusually clean. Combined with the 26-year hepatitis B safety record and the direct COVID-19 blood data, this is why many long COVID and ME/CFS clinics are now using Ta1 as part of immune reset protocols.
If you are in the ME/CFS or long COVID community and have not seen Ta1 discussed, most peptide content focuses on gym use cases. The immune-exhaustion use case is the most evidence-supported application outside hepatitis, and it is largely absent from mainstream coverage.
How Long Does Thymosin Alpha-1 Actually Take to Work?
Most information online is misleading on this. The hepatitis B trials, the most rigorous long-term data available, show something counterintuitive: measurable peak response often appears weeks to months after stopping treatment, not during it.
In the hepatitis B approval trials, the standard 26-week protocol produced a 40.6% complete virological response rate, with peak response measured at week 52 -- six months after the last injection. The immune recalibration Ta1 initiates takes time to translate into measurable biological change.
The realistic timeline for immune support use:
| Timeframe | What changes | How you would know |
|---|---|---|
| Weeks 1-2 | Measurable T-cell marker shifts on bloodwork. Most people feel nothing subjectively. | CD4/CD8 ratio, NK cell activity on labs |
| Weeks 4-8 | Some users report reduced illness frequency, improved energy. Individual variation is high. | Subjective symptom tracking |
| Weeks 12-26 | Full immune recalibration window. The protocol length for hepatitis B, ME/CFS, and post-viral contexts. | Lymphocyte subsets, inflammatory markers |
| Post-protocol | Peak measurable effect in viral clearance and immune function. Response continues building after stopping. | Virological response, clinical outcome measures |
Expecting results at 2-4 weeks and judging the protocol on that window is how most users conclude "Ta1 did nothing." The biology just does not move that fast. For comparison, peptide cycling considerations for longer protocols are covered in our guide on when to pause and when to push a peptide protocol.
Standard Dosing from Clinical Trials
| Context | Dose | Schedule | Duration |
|---|---|---|---|
| Chronic hepatitis B/C (approved use) | 1.6 mg SC | 2x per week | 26 weeks |
| Immune support and longevity use | 1.6 mg SC | 2-3x per week | 12-26 weeks |
| Acute infection or post-viral | 1.6-3.2 mg SC | Daily for 5-14 days | Short course |
| Severe acute pancreatitis (clinical) | 1.6 mg SC | Daily | 5-7 days |
Across 11,000+ subjects, no dose-limiting toxicity has been identified. Injection site reactions -- mild redness, brief soreness -- are the main reported side effect in roughly 5-8% of subjects. That safety profile across four decades is one of the most important things to understand about this peptide.
Can You Actually Get Thymosin Alpha-1 in the US in 2026?
This is the question with the most complicated answer, and the one most articles get wrong.
Ta1 is not FDA-approved for any indication in the US. It holds Orphan Drug designation for several conditions, which is a research status, not approval. In late 2024, the FDA's Pharmacy Compounding Advisory Committee reviewed Ta1 and placed it in Category 2 -- meaning 503A compounding pharmacies could not legally compound it.
February 27, 2026 changed the picture. HHS Secretary RFK Jr. announced that approximately 14 of 19 Category 2 peptides, including Ta1, would be moved back to Category 1. That shift became effective April 23, 2026. Category 1 means a licensed physician can prescribe Ta1 and a 503A compounding pharmacy can legally prepare it by prescription.
That is not the same as drug approval. There is no standardized protocol, no validated indication, and no regulatory guarantee of consistent dosing from pharmacy to pharmacy. A formal PCAC review is scheduled for July 23-24, 2026, which will determine longer-term compounding status.
Globally, Ta1 is approved as Zadaxin by SciClone Pharmaceuticals in 35+ countries -- China, Italy, the Philippines, India, South Korea, and more, primarily for chronic hepatitis B. Those approvals have been in place since the 1990s. For how other countries handle peptide access, our guide on European peptide pharmacy rules in 2026 covers the EU landscape in detail.
The practical path in the US today: a physician writes a prescription (most commonly through a longevity or functional medicine clinic), and a 503A compounding pharmacy fills it. Supply chains are rebuilding post-April 2026. Unregulated research-chemical vendors still exist, but purity is entirely unverified. For the full picture on US peptide legality, our guide on peptide legal status in the US in 2026 covers every category.
Your Immune Genes and Thymosin Alpha-1: What the Data Shows
No large pharmacogenomic trial for Ta1 has ever been published. What exists is mechanistic logic and one meaningful dataset.
The strongest signal comes from the 2021 COVID-19 blood study. HLA-DR expression on immune cells was the most statistically significant marker Ta1 modulated (P=0.001), stronger than IL-6 or CD38 effects alone. That suggests your HLA class II expression level is a meaningful predictor of response. People with high baseline HLA-DR activation -- the hyperactivated immune pattern -- show the largest measurable change.
The IL-6 and IFNG pathways are plausible moderators from the same study. If your genome includes IL-6 promoter variants that raise baseline inflammation, your T cells are more likely to show the activation signature Ta1 specifically addresses. High-expression IFNG variants correlate with the CD38 axis Ta1 recalibrates.
No rsID lookup gives you a precise Ta1 response prediction today. But if your PeptidesDNA report flags elevated immune activation patterns -- high IL-6 risk, HLA variants linked to autoimmune susceptibility -- Ta1 is more likely to be relevant to your biology than it would be for someone with a quiescent immune baseline.
For context on how metabolizer genes affect broader peptide dosing, our guide on CYP3A4 slow metabolizers and peptide protocols covers the pharmacokinetics layer. Ta1 itself is not CYP-dependent, but many peptides in a stack are.
You can see the full Thymosin Alpha-1 profile, evidence summary, and genetic match score at the Ta1 peptide page.
The verdict: Thymosin Alpha-1 is the most clinically tested peptide in the biohacking space and one of the most misunderstood. It is not a general immune booster. It is an immune modulator that works specifically when your immune system is overactivated, exhausted, or stuck in a post-viral loop.
The null sepsis trial did not kill Ta1. It clarified it. The 44% infection reduction in severe acute pancreatitis, the COVID-19 blood data, and the long COVID mechanistic fit all point to one use case: people whose immune systems are simultaneously overactivated and functionally depleted. If that is you, the evidence base behind this peptide is deeper than almost anything else in this space.
Ready to see whether your immune genetics make you a strong Ta1 candidate? Upload your raw DNA file for an instant match score, or order a kit if you do not have genetic data yet.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
What is thymosin alpha-1 used for?
Thymosin Alpha-1 is used primarily for immune modulation in contexts where the immune system is dysregulated. Approved uses in 35+ countries include chronic hepatitis B and C. Off-label uses supported by clinical data include severe acute pancreatitis (44% infection reduction in a 2025 meta-analysis), post-viral immune exhaustion including long COVID, and general immune support in immunocompromised patients. It is not effective as a general-purpose immune booster in healthy adults -- the 2025 TESTS Phase 3 trial confirmed this.
What is the standard thymosin alpha-1 dosage?
The standard dose from clinical trials is 1.6 mg subcutaneous injection, two to three times per week. The hepatitis B approval protocol runs this dose for 26 weeks. For immune support or post-viral contexts, most protocols use the same dose for 12-26 weeks. Short-course protocols for acute infection use 1.6-3.2 mg daily for 5-14 days. No dose-limiting toxicity has been identified across 11,000+ subjects in controlled trials.
How long does thymosin alpha-1 take to work?
Measurable immune marker changes appear in the first 1-2 weeks of treatment. Subjective benefits emerge for some users at weeks 4-8. The full immune recalibration, based on hepatitis B trial data, develops over 12-26 weeks. Counterintuitively, peak measurable response often appears weeks to months after stopping treatment. Judging a Ta1 protocol on a 2-4 week window will systematically underestimate its effects.
Is thymosin alpha-1 legal in the US in 2026?
Yes, with a prescription. In February 2026, HHS announced Ta1 would move back to Category 1 of the FDA compounding framework, effective April 23, 2026. A licensed physician can prescribe it and a 503A compounding pharmacy can legally fill the prescription. This is not FDA drug approval -- it is a restoration of legal compounding access. A formal PCAC review scheduled for July 2026 will determine the longer-term regulatory path.
Does thymosin alpha-1 work for long COVID or ME/CFS?
Mechanistic and early clinical evidence supports this use case, but no large randomized trial specific to long COVID exists yet. A 2023 study found Ta1 restored immune homeostasis in post-acute SARS-CoV-2 patients, specifically addressing the CD38/IFNgamma hyperactivation pattern associated with fatigue and symptom burden. The biological fit is strong: both long COVID and ME/CFS feature the immune exhaustion pattern Ta1 specifically modulates.
What are the side effects of thymosin alpha-1?
Thymosin Alpha-1 has one of the cleanest safety profiles in the peptide space. Across 11,000+ subjects in 30+ trials, no dose-limiting toxicity has been identified. The most common side effect is mild injection site reactions in roughly 5-8% of subjects. Transient fatigue and mild myalgia are reported rarely. One contraindication worth noting: organ transplant recipients should avoid Ta1, as its immune-activating properties could theoretically increase rejection risk.
How is thymosin alpha-1 different from BPC-157 or TB-500?
BPC-157 and TB-500 primarily target tissue repair: tendons, gut lining, blood vessels. They work locally at injury or damage sites. Thymosin Alpha-1 works on the immune system itself, specifically on T-cell function and immune regulatory balance. These are complementary mechanisms, not competing ones. Some longevity protocols combine Ta1 (immune baseline reset) with BPC-157 (tissue repair) for broad coverage. They do not compete for the same pathways.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.